Answers are grounded in this paper and cite their sources.
Evaluates graphene oxide and its modifications for removing pharmaceutical contaminants, indicating their potential effectiveness.
Adsorption properties of graphene oxide (GO) and its organo-modified analog (GO-HDTMA), treated with the hexadecyltrimethylammonium (HDTMA) cationic surfactant, were evaluated for the removal of persistent pharmaceutical products (PPs): an anionic diclofenac (DCF) anti-inflammatory, a cationic metoprolol (MTP) beta-blocker, and a nonionic sulfamethoxazole (SMX) antibiotic. Adsorption isotherms, fitted by Langmuir and Freundlich models, together with FTIR data, demonstrate that both GO and GO-HDTMA are effective adsorbents for DCF. The adsorption is primarily governed by both π–π and van der Waals interactions, leading to saturation of the accessible C sp2 carbon domains at a maximum uptake of 4.2 mmol g−1. In contrast, due to its cationic nature, MTP is not removed using GO-HDTMA, while it is effectively adsorbed at about 0.5 mmol g−1 for GO via electrostatic attractive forces. SMX is adsorbed by both materials, although its uptake remains limited on GO. The presence of hydrophobic domains in GO-HDTMA enhances SMX adsorption through weak intermolecular interactions. These results highlight the tunability of GO-based hybrid materials and their potential for the selective removal of a large spectrum of emerging pharmaceutical contaminants.
No takes yet. Share an insight, caveat, or question.
Fragnaud et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: